Fierce Biotech

R1 zooms out of stealth with $77.5M series A to advance chronic kidney disease treatment

R1 Therapeutics is debuting with an oversubscribed $77.5 million series A financing aimed at advancing its first-in-class ...

R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease

Series A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S. Renal CarePartnership ...
PharmaTimes

R1 Therapeutics launches with $77.5m to advance hyperphosphatemia treatment

R1 Therapeutics has launched with an oversubscribed $77.5 million Series A financing and an exclusive global licence to ...
Healio

FDA approves Xphozah for the treatment of hyperphosphatemia

Please provide your email address to receive an email when new articles are posted on . Ardelyx Inc. has received FDA approval for its phosphate drug Xphozah. The company said it is the first and only ...
Renal & Urology News

Phosphate, Parathyroid Hormone Levels at Dialysis Session Start Vary by Time of Day

Serum levels of phosphate and parathyroid hormone are lower early in the day and higher late in the day, recently reported data suggest. Phosphate and parathyroid hormone (PTH) levels at the start of ...